Simon Volkl

Erlangen, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 93 publications

Universal high-sensitivity CAR T-cell monitoring by targeting linker sequences.

Universal high-sensitivity CAR T-cell monitoring by targeting linker sequences.

Journal: Frontiers in immunology
Published: January 14, 2026

CD19 CAR-T therapy induces remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid syndrome.

CD19 CAR-T therapy induces remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid syndrome.

Journal: Med (New York, N.Y.)
Published: December 03, 2025

FAS-controlled T cells drive lymphoproliferation through glycolysis without effector differentiation.

FAS-controlled T cells drive lymphoproliferation through glycolysis without effector differentiation.

Journal: Journal of human immunity
Published: November 06, 2025

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.

Journal: Nature medicine
Published: September 30, 2025

CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis.

CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis.

Journal: The New England journal of medicine
Published: September 24, 2025

Effects of CD19 CAR T Cell Therapy on Quality of Life and Direct Healthcare Costs in Systemic Lupus Erythematosus: A Preliminary Analysis.

Effects of CD19 CAR T Cell Therapy on Quality of Life and Direct Healthcare Costs in Systemic Lupus Erythematosus: A Preliminary Analysis.

Journal: The Journal of rheumatology
Published: September 04, 2025

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases.

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases.

Journal: Nature medicine
Published: August 19, 2025

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus - Authors' reply.

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus - Authors' reply.

Journal: The Lancet. Rheumatology
Published: July 23, 2025

Long-term follow up of efficiency and safety of CD19-CAR T-cell treatment of systemic lupus erythematosus

Long-term follow up of efficiency and safety of CD19-CAR T-cell treatment of systemic lupus erythematosus

Journal: Zeitschrift fur Rheumatologie
Published: July 18, 2025

Functional differences between CLL- and ALL-derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL-10 as potential modulatory targets.

Functional differences between CLL- and ALL-derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL-10 as potential modulatory targets.

Journal: HemaSphere
Published: July 04, 2025

3D Tumor microenvironment interaction reveals AP-1 complex regulation and contact-mediated reprogramming of bone marrow stromal cells in chronic lymphocytic leukemia.

3D Tumor microenvironment interaction reveals AP-1 complex regulation and contact-mediated reprogramming of bone marrow stromal cells in chronic lymphocytic leukemia.

Journal: HemaSphere
Published: March 26, 2025

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study.

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study.

Journal: The Lancet. Rheumatology
Published: February 19, 2025
Showing 1-12 of 93

Last Updated: 09/26/2026